HER2 IHC testing is critical for guiding clinical decisions in breast, gastric, and other solid tumors.1,2 With evolving clinical advancements, ensuring scoring consistency across the full spectrum of HER2 expression is more important than ever.2

Explore real-world cases, assessment tools, and expert-developed resources to enhance your HER2 IHC scoring confidence.

IHC Atlas: Whole slide images

Examine real-world staining patterns across 100+ expert-selected cases to support scoring accuracy and diagnostic consistency in your practice.

Explore the IHC Atlas

CAP, College of American Pathologists; HER2, human epidermal growth factor receptor 2; IHC, immunohistochemistry.

1. Ko HC, et al. Front Oncol 2025;15:1565872. doi: 10.3389/fonc.2025.1565872. 2. Zhang H, et al. Histopathology 2024;85(1):3-19. 3. CAP. Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. Version: 1.6.0.0.

1. Ko HC, et al. Front Oncol 2025;15:1565872. doi: 10.3389/fonc.2025.1565872. 2. Zhang H, et al. Histopathology 2024;85(1):3-19. 3. CAP. Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. Version: 1.6.0.0.

Her2know Footer Logo

Request an AstraZeneca Medical Affairs Representative Follow-Up